VERNALIS THERAPEUTICS, INC.
BERWYN, PA

About Vernalis Therapeutics Headquartered in Berwyn PA, Vernalis Therapeutics, Inc. is a US subsidiary of Vernalis plc, established to commercialize extended-release formulations of prescription products for the US market. These products are being developed in partnership with New Jersey based Tris Pharma, Inc. The NDA for the lead product, Tuzistra  XR (codeine polistirex and chlorpheniramine polistirex) extended-release oral suspension, CIII, was approved by the FDA on 30 April 2015 and the product was launched into the 2015/2016 cough cold season. Click Vernalis Therapeutics, Inc. was established to distribute prescription pharmaceuticals into the US market.  Our parent company, Vernalis plc, is a UK based company listed on AIM.  The VTI activities were founded on the development and licensing agreement with Tris Pharma, Inc. but the group has subsequently added Moxatag are the perfect team to help Vernalis realise its potential.  They form part of a talented, highly qualified and knowledgeable senior management team.   Within Vernalis Therapeutics, Inc.  We have a talented, experienced, knowledgeable senior management team at Vernalis Therapeutics, Inc. They ensure that the company is well run at all levels. Key members of the management team include: Sandford Sommer joined Vernalis in May 2016. Prior to joining Vernalis, Sandford gained considerable experience during his 24 years at AstraZeneca, including increasingly senior roles in sales and marketing, and general management. Most recently he served as President of AstraZeneca´s Colombia operations where the business experienced rapid growth during his tenure. Prior to Colombia, he served in a variety of leadership roles, including Global Vice President of CNS, Infection and Flu Vaccines. In the US he served as Executive Director for the Seroquel® Franchise, where under his leadership Seroquel XR® became one of the fastest growing atypical antipsychotics, and the team was recognized by Medical Marketing and Media as "Large Pharma Marketing Team of the Year." He has extensive experience building brands and has been instrumental in the success of some of the most successful brands in pharmaceutical history including Seroquel®, Nexium®, and Symbicort®. Mr. Sommer served on the Board of the UK Colombia Trade organization for the last two years. He began his career with sales and management positions at Astra/Merck. Donna Radzik joined Vernalis in February 2014. She oversees all facets of technical operations, including quality, contract manufacturing, regulatory, supply chain and distribution. Donna has extensive experience managing drug substance and product technical development, commercial manufacture/supply chain and global quality systems. Prior to joining Vernalis, Donna headed a consultancy providing pharmaceutical technical and quality support. Donna has also held senior leadership roles at Aveo Oncology, Sanofi Pasteur Biologics (formerly Acambis), UCB Pharma and Celltech/Medeva. Donna has a PhD in Analytical Chemistry from Purdue University.  Pascal Borderies joined Vernalis in September 2014. A physician by training who initially focused on clinical pharmacology, Pascal provides leadership and has oversight for all clinical development, medical affairs, regulatory and pharmacovigilance activities of the commercial and development portfolio of the company. Prior to joining Vernalis, Pascal held positions of increasing responsibility on both the R&D and the business sides in various pharma/biotech companies, managing prescriptions and OTC products in Primary Care and other Specialty markets. Most recently, Pascal was the Senior Director Clinical Strategy & Development in the Pharmaceutical Technologies division of Aptalis Pharma, Inc. Before, he was Director – Global Head Cough-Cold Respiratory, Pain and New Growth Opportunities and Director Search and Evaluate in the OTC Business Unit of Novartis Consumer Health, Inc., Senior Director Commercial Development Allergy, Respiratory, Primary Care and Women's Health at Schering-Plough Corp., Executive Director Commercial Development & Marketing/BD at Genaissance Pharmaceuticals Inc., and Director Marketing at Sanofi-Synthélabo Inc. Pascal earned his Medical Degree from the School of Medicine of the University Paris 12 Val de Marne in France Vernalis plc, the parent company of Vernalis Therapeutics, Inc. is one of the UK’s leading pharmaceutical companies, Vernalis takes promising product candidates along a commercially-focused path to market. We derive pipeline candidates both from successful collaborations with a number of global pharmaceutical businesses, our own research activities and from in-licensing.  Build a profitable and cash generative business Develop and commercialise low development-risk late-stage differentiated pharmaceutical products for unmet medical needs in the US VERNALIS THERAPEUTICS, INC. CORPORATE GOVERNANCE Vernalis Therapeutics, Inc. (VTI) is committed to maintaining the highest ethical standards in its dealings with all parties involved in the Company’s business activities, including employees, vendors, contractors and other third parties with which VTI interacts.  VTI’s Compliance Program and Code of Business Conduct and Ethics are intended to promote honest and ethical conduct among all individuals employed by VTI.  VTI expects every individual, all staff and management and contract workers (full time or temporary) to comply with established compliance governance program requirements and all other applicable laws, regulations and Company policies. VTI recognizes its employees are a valuable asset of the Company.  We expect all employees to be ethical, innovative and hard working.  We work to retain and recruit individuals by providing appropriate compensation, growth opportunities and a diverse workplace free from bias, discrimination, and harassment. VTI is committed to providing equal opportunity in employment to all employees and applicants.  This commitment applies to recruitment, hiring, employment and employment-related decisions. We are also committed to complying with all applicable laws regarding nondiscrimination in employment.